|
1
|
Polyak MJ, Li H, Shariat N and Deans JP:
CD20 homo-oligomers physically associate with the B cell antigen
receptor. Dissociation upon receptor engagement and recruitment of
phosphoproteins and calmodulin-binding proteins. J Biol Chem.
283:18545–18552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li H, Ayer LM, Lytton J and Deans JP:
Store-operated cation entry mediated by CD20 in membrane rafts. J
Biol Chem. 278:42427–42434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tedder TF, Boyd AW, Freedman AS, Nadler LM
and Schlossman SF: The B cell surface molecule B1 is functionally
linked with B cell activation and differentiation. J Immunol.
135:973–979. 1985.PubMed/NCBI
|
|
4
|
Rawstron AC, Owen RG, Davies FE, Johnson
RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS
and Morgan GJ: Circulating plasma cells in multiple myeloma:
Characterization and correlation with disease stage. Br J Haematol.
97:46–55. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chu PG, Loera S, Huang Q and Weiss LM:
Lineage determination of CD20- B-Cell neoplasms: An
immunohistochemical study. Am J Clin Pathol. 126:534–544. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kato Y and Kaneko MK: A cancer-specific
monoclonal antibody recognizes the aberrantly glycosylated
podoplanin. Sci Rep. 4:59242014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Itai S, Fujii Y, Nakamura T, Chang YW,
Yanaka M, Saidoh N, Handa S, Suzuki H, Harada H, Yamada S, et al:
Establishment of CMab-43, a sensitive and specific Anti-CD133
monoclonal antibody, for immunohistochemistry. Monoclon Antib
Immunodiagn Immunother. 36:231–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamada S, Itai S, Nakamura T, Yanaka M,
Kaneko MK and Kato Y: Detection of high CD44 expression in oral
cancers using the novel monoclonal antibody, C44Mab-5. Biochem
Biophys Rep. 14:64–68. 2018.PubMed/NCBI
|
|
9
|
Yamada S, Itai S, Nakamura T, Yanaka M,
Chang YW, Suzuki H, Kaneko MK and Kato Y: Monoclonal antibody
L1Mab-13 detected human PD-L1 in lung cancers. Monoclon Antib
Immunodiagn Immunother. 37:110–115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Furusawa Y, Yamada S, Itai S, Sano M,
Nakamura T, Yanaka M, Fukui M, Harada H, Mizuno T, Sakai Y, et al:
PMab-210: A monoclonal antibody against pig podoplanin. Monoclon
Antib Immunodiagn Immunother. 38:30–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furusawa Y, Kaneko MK, Nakamura T, Itai S,
Fukui M, Harada H, Yamada S and Kato Y: Establishment of a
monoclonal antibody PMab-231 for tiger podoplanin. Monoclon Antib
Immunodiagn Immunother. 38:89–95. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Furusawa Y, Takei J, Sayama Y, Yamada S,
Kaneko MK and Kato Y: Development of an anti-bear podoplanin
monoclonal antibody PMab-247 for immunohistochemical analysis.
Biochem Biophys Rep. 18:1006442019.PubMed/NCBI
|
|
13
|
Furusawa Y, Yamada S, Itai S, Nakamura T,
Takei J, Sano M, Harada H, Fukui M, Kaneko MK and Kato Y:
Establishment of a monoclonal antibody PMab-233 for
immunohistochemical analysis against Tasmanian devil podoplanin.
Biochem Biophys Rep. 18:1006312019.PubMed/NCBI
|
|
14
|
Furusawa Y, Yamada S, Itai S, Nakamura T,
Yanaka M, Sano M, Harada H, Fukui M, Kaneko MK and Kato Y:
PMab-219: A monoclonal antibody for the immunohistochemical
analysis of horse podoplanin. Biochem Biophys Rep.
18:1006162019.PubMed/NCBI
|
|
15
|
Kato Y, Furusawa Y, Itai S, Takei J,
Nakamura T, Sano M, Harada H, Yamada S and Kaneko MK: Establishment
of an anticetacean podoplanin monoclonal antibody PMab-237 for
immunohistochemical analysis. Monoclon Antib Immunodiagn
Immunother. 38:108–113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kato Y, Furusawa Y, Yamada S, Itai S,
Takei J, Sano M and Kaneko MK: Establishment of a monoclonal
antibody PMab-225 against alpaca podoplanin for immunohistochemical
analyses. Biochem Biophys Rep. 18:1006332019.PubMed/NCBI
|
|
17
|
Kato Y, Yamada S, Furusawa Y, Itai S,
Nakamura T, Yanaka M, Sano M, Harada H, Fukui M and Kaneko MK:
PMab-213: A monoclonal antibody for immunohistochemical analysis
against pig podoplanin. Monoclon Antib Immunodiagn Immunother.
38:18–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tedder TF, McIntyre G and Schlossman SF:
Heterogeneity in the B1 (CD20) cell surface molecule expressed by
human B-lymphocytes. Mol Immunol. 25:1321–1330. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Xu H, Liu T, Huang M, Butter PP,
Li C, Zhang L, Kao GD, Gong Y, Maity A, et al: Temporal DNA-PK
activation drives genomic instability and therapy resistance in
glioma stem cells. JCI Insight. 3:980962018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reff ME, Carner K, Chambers KS, Chinn PC,
Leonard JE, Raab R, Newman RA, Hanna N and Anderson DR: Depletion
of B cells in vivo by a chimeric mouse human monoclonal antibody to
CD20. Blood. 83:435–445. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Keating GM: Rituximab: A review of its use
in chronic lymphocytic leukaemia, low-grade or follicular lymphoma
and diffuse large B-cell lymphoma. Drugs. 70:1445–1476. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Itai S, Ohishi T, Kaneko MK, Yamada S, Abe
S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, et al:
Anti-podocalyxin antibody exerts antitumor effects via
antibody-dependent cellular cytotoxicity in mouse xenograft models
of oral squamous cell carcinoma. Oncotarget. 9:22480–22497. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaminski MS, Estes J, Zasadny KR, Francis
IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, et
al: Radioimmunotherapy with iodine (131)I tositumomab for relapsed
or refractory B-cell non-Hodgkin lymphoma: Updated results and
long-term follow-up of the University of Michigan experience.
Blood. 96:1259–1266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gordon LI, Molina A, Witzig T,
Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G and
White CA: Durable responses after ibritumomab tiuxetan
radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up
of a phase 1/2 study. Blood. 103:4429–4431. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Coiffier B, Lepretre S, Pedersen LM,
Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J,
Holowiecki J, Hellmann A, et al: Safety and efficacy of ofatumumab,
a fully human monoclonal anti-CD20 antibody, in patients with
relapsed or refractory B-cell chronic lymphocytic leukemia: A phase
1–2 study. Blood. 111:1094–1100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mossner E, Brunker P, Moser S, Püntener U,
Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E,
et al: Increasing the efficacy of CD20 antibody therapy through the
engineering of a new type II anti-CD20 antibody with enhanced
direct and immune effector cell-mediated B-cell cytotoxicity.
Blood. 115:4393–4402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Link BK and Friedberg JW: Monoclonal
antibodies in lymphoma: The first decade. Semin Hematol. 45:71–74.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kennedy GA, Tey SK, Cobcroft R, Marlton P,
Cull G, Grimmett K, Thomson D and Gill D: Incidence and nature of
CD20-negative relapses following rituximab therapy in aggressive
B-cell non-Hodgkin's lymphoma: A retrospective review. Br J
Haematol. 119:412–416. 2002. View Article : Google Scholar : PubMed/NCBI
|
